Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR...

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• Non-small-cell lung cancer (NSCLC) often involves mutations in the epidermal growth factor receptor (EGFR), leading to uncontrolled signaling.
• EGFR exon 19 deletions are a common mutation driving NSCLC progression.
• Gefitinib resistance is a significant challenge in treating EGFR-mutated NSCLC.

Purpose of the Study:

• To design and evaluate a DNAzyme for suppressing mutant EGFR expression in NSCLC.
• To investigate the dual mechanism of action of the DNAzyme, including EGFR downregulation and immune activation.
• To assess the efficacy of the DNAzyme in reducing cancer cell viability and inducing apoptosis.

Main Methods:

• Design of a specific DNAzyme (Ex19del Dz) targeting mutant EGFR mRNA.
• Transfection of the DNAzyme into gefitinib-resistant NSCLC cells with EGFR exon 19 deletions.
• Analysis of EGFR expression, downstream signaling pathways, and Toll-like receptor 9 (TLR9) activation.

Main Results:

• The DNAzyme specifically cleaved mutant EGFR mRNA, leading to decreased EGFR expression and inhibited downstream signaling.
• Ex19del Dz induced cancer cell apoptosis by both EGFR downregulation and immunostimulation via TLR9 activation.
• The DNAzyme demonstrated efficacy in gefitinib-resistant NSCLC cells harboring EGFR exon 19 deletions.

Conclusions:

• The designed DNAzyme (Ex19del Dz) offers a dual therapeutic strategy for EGFR-mutated NSCLC.
• Targeting mutant EGFR mRNA and simultaneously activating the immune system via TLR9 presents a promising approach.
• This DNAzyme holds potential for overcoming gefitinib resistance in NSCLC treatment.